Tesamorelin China
Tesamorelin China Tesamorelin China Tesamorelin China Tesamorelin China Tesamorelin China
Tesamorelin China Tesamorelin China Tesamorelin China Tesamorelin China Tesamorelin China Tesamorelin China

Tesamorelin China

11.0 USD ($)/Piece

Product Details:

  • CAS No 218949-48-5
  • Poisonous NO
  • Ingredients Tesamorelin
  • Usage Tesamorelin (sold under brand names like Egrifta SV and Egrifta WR) is a synthetic growth hormone-releasing hormone (GHRH) analog used to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Approved Medical Uses HIV-Associated Lipodystrophy: FDA-approved to decrease excess deep belly (visceral adipose tissue) in HIV-infected adults experiencing fat redistribution. Weight Neutrality: It targets visceral fat and waist circumference but is not a general weight-loss or fat-burning drug; it typically has a weight-neutral effect on total body weight. Administration Route: Given as a subcutaneous injection (under the skin), typically in the abdominal area below the belly button. Formulations: Egrifta SV: Prescribed as a liquid mixture prepared using sterile water for injection. Egrifta WR: Prepared using bacteriostatic water and supplied for multi-day usage. Practice: Injection sites must be rotated regularly. Mechanism of Action Stimulates the anterior pituitary gland to produce and release endogenous growth hormone in natural pulses. Increases insulin-like growth factor 1 (IGF-1) levels, which promotes the breakdown of deep visceral fat around internal organs. Common Side Effects & Risks Side Effects: Joint and muscle pain, swelling/fluid retention (peripheral edema), injection site reactions, and tingling or numbness in the extremities. Metabolic Impact: Can alter blood glucose levels and insulin sensitivity, requiring caution or monitoring in patients with diabetes. Contraindications: Active cancer, a history of pituitary tumors or surgery, pregnancy, or known allergies to the components.
  • Physical Form Powder
  • Solubility Tesamorelin is a water-soluble polypeptide with good solubility in both polar and hydrophilic solvents.
  • Grade Research Grade
  • Click to View more
X

Tesamorelin China Price And Quantity

  • 11.0 USD ($)/Piece
  • 10 Piece

Tesamorelin China Product Specifications

  • Tesamorelin is a water-soluble polypeptide with good solubility in both polar and hydrophilic solvents.
  • C221H366N72O67S
  • Other
  • 18 Months
  • 603-809-2
  • Powder
  • Tesamorelin (sold under brand names like Egrifta SV and Egrifta WR) is a synthetic growth hormone-releasing hormone (GHRH) analog used to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Approved Medical Uses HIV-Associated Lipodystrophy: FDA-approved to decrease excess deep belly (visceral adipose tissue) in HIV-infected adults experiencing fat redistribution. Weight Neutrality: It targets visceral fat and waist circumference but is not a general weight-loss or fat-burning drug; it typically has a weight-neutral effect on total body weight. Administration Route: Given as a subcutaneous injection (under the skin), typically in the abdominal area below the belly button. Formulations: Egrifta SV: Prescribed as a liquid mixture prepared using sterile water for injection. Egrifta WR: Prepared using bacteriostatic water and supplied for multi-day usage. Practice: Injection sites must be rotated regularly. Mechanism of Action Stimulates the anterior pituitary gland to produce and release endogenous growth hormone in natural pulses. Increases insulin-like growth factor 1 (IGF-1) levels, which promotes the breakdown of deep visceral fat around internal organs. Common Side Effects & Risks Side Effects: Joint and muscle pain, swelling/fluid retention (peripheral edema), injection site reactions, and tingling or numbness in the extremities. Metabolic Impact: Can alter blood glucose levels and insulin sensitivity, requiring caution or monitoring in patients with diabetes. Contraindications: Active cancer, a history of pituitary tumors or surgery, pregnancy, or known allergies to the components.
  • Pharmaceutical
  • Peptides
  • Research Grade
  • Not less than 99.00%
  • Tesamorelin
  • 218949-48-5
  • NO
  • Odorless
  • Freezer
  • 4.5~7.4
  • Tesamorelin is a synthetic peptide and a long-lasting analog of growth hormone-releasing hormone (GHRH). It is primarily recognized and FDA-approved for its ability to significantly reduce visceral abdominal fat in HIV-infected adult patients suffering from lipodystrophy. The pharmacological, chemical, and clinical properties of tesamorelin break down as follows: 1. Chemical & Structural Properties Amino Acid Sequence: It is a synthetic polypeptide comprised of 44 amino acids. Its structure mimics the natural sequence of human GHRH (1-44). Molecular Modification: The peptide is modified at its N-terminus with a trans-3-hexenoyl group. Enzymatic Stability: This N-terminal modification is a critical property; it protects the molecule from rapid cleavage by the enzyme dipeptidyl peptidase-4 (DPP-4). Consequently, tesamorelin is much more stable and potent, possessing a significantly extended half-life compared to natural, endogenous GHRH. 2. Pharmacological Mechanism of Action Pituitary Stimulation: Tesamorelin acts directly upstream on the anterior pituitary gland by binding with high affinity to human GHRH receptors. Pulsatile GH Release: Instead of overwhelming the body like direct human growth hormone (hGH) injections, tesamorelin prompts the pituitary to synthesize and release the body's own endogenous growth hormone (GH) in a natural, pulsatile manner. IGF-1 Regulation: The surge in growth hormone stimulates the liver to produce insulin-like growth factor 1 (IGF-1). 3. Metabolic & Biological Properties Targeted Lipolysis: The elevation of GH and IGF-1 accelerates lipid metabolism. Tesamorelin triggers hormone-sensitive lipase and fatty acid oxidation, which specifically breaks down visceral adipose tissue (VAT) the dangerous, deep fat surrounding internal organs. Adipose Selectivity: A distinct property of tesamorelin is its high selectivity. It significantly reduces visceral fat and liver fat, while leaving the protective subcutaneous fat (fat directly under the skin) and lean muscle mass mostly untouched or preserved. Homeostatic Feedback: Because it prompts natural production upstream, the body's intrinsic feedback loop remains intact, mitigating some of the toxicities associated with direct synthetic GH excess. 4. Clinical Indications & Application Approved Indication: It is indicated exclusively for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss or obesity drug. Administration: It must be administered as a daily subcutaneous injection, commonly formulated as Egrifta SV or Egrifta WR. Research Properties: Outside its main indication, clinical studies have evaluated tesamorelin for its potential properties in treating Nonalcoholic Fatty Liver Disease (NAFLD), improving cognitive executive function in older adults, and supporting peripheral nerve injury recovery.
  • White powder
  • 2937190099

Tesamorelin China Trade Information

  • Shenzhen or Guangzhou
  • Telegraphic Transfer (T/T), Western Union
  • 10000 Piece Per Week
  • 5 Days
  • No
  • Free samples available with shipping and taxes paid by the buyer
  • 10 vials per kit
  • North America, Western Europe, Asia, Australia
  • GMP, ISO

Other Products in 'Peptide Preparations' category



arrow